Delivery Order SPE2DB20D2014-SPE2DB25FC93Y
- Not listed
- The Defense Logistics Agency awarded a delivery order valued at $4,665.23 to AmerisourceBergen Drug Corp on August 11, 2025, for the supply of Trelegy Ellipta 100-62.5-25, a combination inhalation powder used in the treatment of chronic obstructive pulmonary disease. This non-competitive delivery order represents a firm fixed price transaction with a completion date of August 12, 2025, and will be performed at the contractor's corporate office location in Conshohocken, Pennsylvania. This...
- The Defense Logistics Agency awarded a delivery order valued at $5,582.67 to AmerisourceBergen Drug Corp for Trelegy Ellipta 100-62.5-25, a combination inhalation powder medication used to treat chronic obstructive pulmonary disease. This competitively awarded, firm fixed-price delivery order is set to be completed by August 26, 2025, just one day after the award date of August 25, 2025. The pharmaceutical will be delivered to Conshohocken, Pennsylvania, the location of AmerisourceBergen's...
- The Defense Logistics Agency awarded a delivery order valued at $1,920.61 to AmerisourceBergen Drug Corp for Trelegy Ellipta 200-62.5-25, a combination inhalation powder medication used to treat chronic obstructive pulmonary disease. The award, issued on July 25, 2025, with an ultimate completion date of July 28, 2025, represents a firm fixed price delivery order with no set-aside designation. The contract is being performed at AmerisourceBergen's corporate office location in Conshohocken,...
- The Defense Logistics Agency awarded a delivery order valued at $1,671.43 to AmerisourceBergen Drug Corp on August 21, 2025, for the supply of Trelegy Ellipta 100-62.5-25 inhalation powder in a 60-dose configuration. This is a firm fixed-price, competitively awarded delivery order with no set-aside designation, with an ultimate completion date of August 22, 2025. The award is performed at AmerisourceBergen's corporate office location in Conshohocken, Pennsylvania. This delivery order is issued...
- The U.S. Defense Logistics Agency Medical Supply Chain awarded a firm fixed-price delivery order to AmerisourceBergen Drug Corp on August 14, 2025, for the supply of Trelegy Ellipta 200-62.5-25 inhalation powder, a combination respiratory medication used to treat chronic obstructive pulmonary disease. The contract, valued at $22,743.24 with an ultimate completion date of August 15, 2025, was competitively awarded without set-aside designation and will be performed at the contractor's corporate...
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp on July 23, 2025, for pharmaceutical supplies valued at $2,186.63. The order is for Trelegy Ellipta 200-62.5-25, a combination inhalation powder medication used to treat chronic obstructive pulmonary disease, with an ultimate completion date of July 24, 2025. This firm fixed price delivery order represents a non-competitive award utilizing AmerisourceBergen's existing contract vehicle and reflects the...
- The Defense Logistics Agency awarded a $23,885.70 delivery order to AmerisourceBergen Drug Corp on August 7, 2025, for the supply of Trelegy Ellipta 100-62.5-25, a combination inhalation powder used to treat chronic obstructive pulmonary disease. This non-set-aside contract utilizes firm fixed pricing and is scheduled for completion by August 8, 2025, with performance taking place at the contractor's corporate office in Conshohocken, Pennsylvania. The delivery order is issued under...
- The Defense Logistics Agency awarded a $3,931.56 delivery order to AmerisourceBergen Drug Corp on August 22, 2025, for the supply of Trelegy Ellipta 200-62.5-25 inhalation powder (60-count package), with completion targeted for August 25, 2025. This competitively awarded, firm fixed-price delivery order represents a child contract under AmerisourceBergen's larger Indefinite Delivery Contract (IDC) with DLA Troop Support Medical, designated SPE2DX and valued at $999,999,999.00 through December...
- The Defense Logistics Agency (DLA) awarded a delivery order valued at $14,814.31 to AmerisourceBergen Drug Corp for Trelegy Ellipta 100-62.5-25 60S, a combination inhalation powder medication used to treat chronic obstructive pulmonary disease. This firm fixed-price delivery order, issued on September 9, 2025, with an ultimate completion date of September 10, 2025, represents a non-competitive award under AmerisourceBergen's existing contract vehicle. The place of performance is located in...
- The Defense Logistics Agency awarded a delivery order valued at $34,728.79 to AmerisourceBergen Drug Corp for the supply of Trelegy Ellipta 100-62.5-25, a combination inhalation powder medication used primarily for chronic obstructive pulmonary disease management. This firm fixed-price delivery order, with an ultimate completion date of August 21, 2025, was awarded on August 20, 2025, through competitive procedures with no set-aside designation. The contract is being performed at...
- SPE2DB20D2014Indefinite Delivery Contract
- SPE2DB20D2014-SPE2DB25FC93YDelivery Order
The Defense Logistics Agency awarded a delivery order valued at $39,958.00 to AmerisourceBergen Drug Corp on September 8, 2025, for the supply of Trelegy Ellipta 200-62.5-25, a combination inhalation powder medication used in the treatment of chronic obstructive pulmonary disease. This competitive, non-set-aside delivery order is set to be completed by September 9, 2025, and will be fulfilled from the vendor's corporate office location in Conshohocken, Pennsylvania. The award represents a continuation of AmerisourceBergen's critical role in supporting federal medical procurement through competitively awarded contracts. This delivery order is executed under AmerisourceBergen's larger Indefinite Delivery Contract (IDC) with DLA Troop Support Medical, valued at $999,999,999.00 and extending through December 2026. This prime pharmaceutical supply agreement enables AmerisourceBergen to distribute a comprehensive range of medications and medical supplies to support military healthcare operations globally, including pharmaceuticals across multiple therapeutic domains. The company's position as a major pharmaceutical distributor demonstrates its capability to fulfill federal medical supply requirements across the Defense Health Agency and other government healthcare systems through this flexible contract vehicle.
Mod # | Description | ReasonForModification | Federal Obligation | Date |
|---|---|---|---|---|
| Not listed | Not listed | $40.0k | 9/8/25 |